Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 101
Updated:12/21/2018
Start Date:September 21, 2017
End Date:November 2020
Contact:Tiffany Colvin
Email:TIFFANY.COLVIN@UCDENVER.EDU
Phone:720-848-0664

Use our guide to learn which trials are right for you!

Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer

This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant
plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced
AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment.

This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant
plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced
AR+/ER+/Her2- BC who will have local surgery after ~4 months on treatment. After consent, all
patients will get a tissue biopsy, and than half the patients will get fulvestrant alone
(standard dosing) and the other half of the patients will get fulvestrant plus enzalutamide.
At ~4 weeks, a biopsy will be done and therapy will be continued. Hormone therapy will
continue for ~4 months at which point the patients will undergo surgical resection.

Inclusion Criteria:

- ER+ Her2- breast cancer

- Stage at least T2 or greater

- Planned to get local surgery

- Postmenopausal, or if pre- or peri- menopausal, then will need to have concurrent
ovarian suppression.

- At least 18 years of age

- Not on anticoagulants

- PS 0-2

- Able to swallow study drug and comply with study requirements

- ANC >1000/uL, platelets >75,000/uL at screening visit

- Total bilirubin < 1.5 times upper limit of normal (ULN) at the screening visit unless
an alternate nonmalignant etiology exists (eg, Gilbert's disease)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or <
5 times ULN if patient has documented liver metastases

- Creatinine < 1.5 times ULN

- INR < 1.5 times ULN, or if on warfarin, can safely transition off for biopsy

- Willing to donate blood for research at 4 time points

- Willing to undergo core biopsies for research at study entry and at ~4 weeks.

- Willing to donate tissue to research from the surgical specimen

- Written informed consent obtained prior to biopsies and blood samples

Exclusion Criteria:

- Current or previously treated brain or leptomeningeal metastases

- History of seizures

- Prior treatment with an anti-androgen (abiraterone, ARN-509, bicalutamide,
enzalutamide, ODM-201, TAK-448, TAK-683, TAK-700, VT-464).

- Systemic estrogens or androgens within 14 days before initiating therapy. Vaginal
estrogens are allowed if necessary for patient comfort.
We found this trial at
3
sites
Aurora, Colorado 80045
Principal Investigator: Anthony D Elias, MD
Phone: 720-848-0664
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Germantown, Tennessee 38138
Principal Investigator: Gregory Vidal, MD
?
mi
from
Germantown, TN
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Monica Fornier, MD
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials